14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property
An ecosystem built around the Cellvizio® platform, enabling partners to develop advanced AI models
Paris and Boston, July 21, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that it has been granted the 14th U.S. patent1 for real-time AI-based enhancement of Confocal Laser Endomicroscopy (CLE) image sequences, continuing to expand its intellectual property portfolio in the field of artificial intelligence.
With this new technological asset, which focuses on the cognitive interface between doctors and machines, Mauna Kea Technologies is reinforcing its position at the heart of all rapid developments in centers of excellence in AI applied to Cellvizio imaging.
This latest milestone builds upon the Company’s recent advancements, including the previously announced major AI breakthrough with Cellvizio for risk stratification of malignant pancreatic cystic lesions. By strengthening its platform’s core technology, Mauna Kea Technologies is positioning itself as an essential partner and catalyst for the entire AI research and development ecosystem, enabling third parties to build high-value applications on the Cellvizio platform.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies commented: “This 14th patent is perfectly aligned with our strategy of building the technological backbone for an AI-powered Cellvizio ecosystem. By enhancing the critical physician-machine interface, this patent further strengthens Cellvizio as a powerful and intuitive foundation for our partners, present and future.”
1 Filing number US-D1082842
